Alpha 2.0
Login Register
» Articles » PMID: 35857557

End Animal Testing for Biosimilar Approval

Overview
Journal Science
Specialty Science
Date 2022 Jul 20
PMID 35857557
Authors
Sarfaraz K Niazi
Affiliations
Soon will be listed here.
Citing Articles

Global Harmonization of Biosimilar Development by Overcoming Existing Differences in Regional Regulatory Requirements - Outcomes of a Descriptive Review.

Kirchlechner T, Cohen H Ther Innov Regul Sci. 2025; 59(2):245-255.

PMID: 39821881 PMC: 11880096. DOI: 10.1007/s43441-024-00740-4.

Advice to the US FDA to Allow US Pharmacopeia to Create Biological Product Specifications (BPS) to Remove Side-by-Side Analytical Comparisons of Biosimilars with Reference Products.

Niazi S Pharmaceutics. 2024; 16(8).

PMID: 39204358 PMC: 11360437. DOI: 10.3390/pharmaceutics16081013.

A Critical Analysis of the FDA's Omics-Driven Pharmacodynamic Biomarkers to Establish Biosimilarity.

Niazi S Pharmaceuticals (Basel). 2023; 16(11).

PMID: 38004421 PMC: 10675618. DOI: 10.3390/ph16111556.

The FDA's New Guideline "Generally Accepted Scientific Knowledge" (GASK): An Opportunity to Expedite the Approval of Biosimilars.

Niazi S Pharmaceuticals (Basel). 2023; 16(11).

PMID: 38004383 PMC: 10674418. DOI: 10.3390/ph16111517.

A Proposed Global Medicines Agency (GMA) to Make Biological Drugs Accessible: Starting with the League of Arab States.

Niazi S Healthcare (Basel). 2023; 11(14).

PMID: 37510516 PMC: 10379659. DOI: 10.3390/healthcare11142075.